🇺🇸

US SEC Filing Intelligence

· daily

All HHS Contracts — July 03, 2026

This digest covers two HHS contracts totaling $4.01 billion, with a dominant $3.52 billion defense-related award to RAPID DEPLOYMENT INC that accounts for 87.7% of the total obligation, signaling a major, likely urgent national security-linked procurement within the civilian health agency. The second contract, a $491.8 million firm-fixed-price award to MANHATTAN TORCON A JOINT VENTURE for CDC high-containment lab construction, reflects sustained federal investment in biodefense infrastructure. The highest-conviction signal is the sheer scale of the RAPID DEPLOYMENT INC award, which dwarfs typical HHS contracts and suggests a critical, possibly sole-source or emergency-driven mission. Key risks include the unknown competitive dynamics and pricing structure of the RAPID DEPLOYMENT INC contract, and the high execution risk of the fixed-price lab construction project, which could lead to cost overruns or margin pressure for the joint venture's parent entities.

2 total filings
· daily

All DOE Contracts — July 03, 2026

The single contract analyzed, a $900 million firm fixed-price delivery order from the Department of Energy to AMERICAN CENTRIFUGE OPERATING, LLC for domestic HALEU production, represents a fully civilian allocation with zero defense-related awards. The dominant sector theme is U.S. nuclear fuel supply chain reshoring, supported by a high-conviction bullish signal (8/10). Key risks include the fixed-price execution burden on a small business recipient and the long 10-year performance period amid potential policy shifts. Investors should monitor AMERICAN CENTRIFUGE’s ability to manage cost overruns on a $90 million annual contract, as any performance failure could delay DOE’s HALEU goals.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 03, 2026

The five mega-contracts totaling $5.88 billion reveal a predominantly civilian federal spending pattern, with only 1 of 5 contracts defense-related (HHS/CDC, though defense-funded). The dominant theme is energy security and biodefense infrastructure, led by a $3.52B HHS award to RAPID DEPLOYMENT INC and a $900M DOE contract to AMERICAN CENTRIFUGE OPERATING for domestic HALEU production. The highest-conviction signal is the long-term, policy-aligned revenue stream for AMERICAN CENTRIFUGE, though its fixed-price structure and small-business status introduce execution risk. A key risk is the $491.8M CDC lab contract to MANHATTAN TORCON JV, which carries high fixed-price execution risk on a complex construction project. Overall, the digest points to growing civilian agency investment in strategic domestic capabilities (nuclear fuel, biodefense labs) rather than traditional defense procurement.

5 total filings
· daily

High-Value Federal Grants ($5M+) — July 03, 2026

This digest of 5 high-value federal grants ($5.9B total) reveals a heavy civilian skew (4 of 5 contracts from HHS, DOE, Commerce, NASA), with only 1 defense-related award (RAPID DEPLOYMENT INC at $3.5B). The dominant theme is U.S. energy security and infrastructure: DOE's $900M HALEU contract to AMERICAN CENTRIFUGE OPERATING signals a multi-year push for domestic nuclear fuel supply, while CDC's $492M high-containment lab build-out underscores biodefense infrastructure spending. The highest-conviction bullish signal is the American Centrifuge contract due to its policy alignment and predictable revenue stream, but it carries medium execution risk from firm-fixed pricing. Key watch item: KBR's $365M NASA contract expires November 2024, posing renewal risk for the contractor.

5 total filings
· daily

DOE Energy Grants — July 03, 2026

This digest covers a single, high-conviction civilian contract: a $900 million firm fixed-price delivery order from the Department of Energy to AMERICAN CENTRIFUGE OPERATING, LLC for domestic HALEU production over 10 years. The aggregate $900 million is entirely civilian, with no defense-related awards. The dominant theme is U.S. energy security and nuclear fuel supply chain resilience. The highest-conviction signal is the long-term, $90 million annual revenue stream for a small business, though the firm fixed-price structure introduces material execution risk. Key watch items include the company's ability to manage fixed-price performance risk and potential follow-on contracts in the domestic nuclear fuel market.

1 total filings
· daily

All NASA Contracts — July 03, 2026

The sole NASA contract analyzed for July 3, 2026, is a $364.7 million cost-plus-fixed-fee award to KBR WYLE Services, LLC (KBR, Inc.) from NASA Ames Research Center for R&D and project management support. This is a civilian agency contract with no defense exposure, representing a long-term, stable revenue stream for KBR but with limited upside due to the cost-plus pricing structure. The highest-conviction signal is neutral, as the contract is nearing its November 2024 end date, posing renewal risk despite high funding certainty. A key watch item is KBR's ability to secure a follow-on award, which will be critical for maintaining its NASA revenue stream.

1 total filings
· daily

Global High-Priority Regulatory Events — July 03, 2026

The July 3, 2026, digest reveals a market bifurcated between aggressive corporate action (M&A, capital restructuring) and deepening distress in specific sectors. A clear theme is the consolidation of strategic capabilities, with several large-cap companies (Samvardhana Motherson, Prestige Estates, Inventurus) executing multi-jurisdictional acquisitions to expand global footprints, though many financial terms remain undisclosed. Concurrently, the Indian real estate and entertainment sectors show acute stress: Mediaone Global Entertainment faces a high-materiality SEBI fraud probe alleging financial fabrication from a near-zero revenue base, while religious infrastructure defaults (Simbhaoli Sugars) and repeat insolvency filings (BIL Vyapar, Spectra Industries) underscore a rising tide of credit events. Notably, the capital restructuring at Sikozy Realtors (90% share capital reduction) is a non-cash balance-sheet repair that does not signal new insolvency. Overall, this is a digest of 'haves' (acquirers with cash and vision) and 'have-nots' (companies in CIRP or under regulatory fire), suggesting investors should favor companies with demonstrated cash flows and disclosed financials over those reliant on opaque turnaround narratives.

28 high priority 28 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 03, 2026

The overnight filing period reveals a significant cluster of insider selling activity, particularly concentrated in CoreWeave, Spyre Therapeutics, and ASP Isotopes, raising caution flags for these names. A major capital return event is unfolding at Janus Henderson, with two directors disposing of over $50M in stock back to the issuer, signaling a potential large-scale buyback or restructuring. The most impactful corporate action is the announced merger between Passage BIO and Remix Therapeutics, creating a new entity (RMTX) and offering a contingent value right to existing PASG shareholders, which represents a high-conviction catalyst. Period-over-period trends are limited in this filing set, but the insider trading patterns show a clear bearish tilt, with 14 negative transactions versus only 1 positive purchase. The data suggests a defensive posture among corporate insiders in growth and biotech names, while financial and utility sectors show routine, non-alarming insider activity. Overall, the digest points to heightened risk in high-growth names and a potential opportunity in the Passage BIO/Remix merger arbitrage.

48 high priority 2 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 02, 2026

During the single-day period of July 2, 2026, the FDA issued one approval classified as 'Other' (FALLBACK-type) for Viridian Therapeutics' veligrotug-vvze (LUMVOA), which was also designated as an NME. No biosimilars or label expansions were approved. The sole approval is a bullish signal for Viridian, though the lack of disclosed commercial data (peak sales, pricing, exclusivity) limits the immediate investment thesis. The dominant risk is the absence of a clear market position or revenue catalyst, making this a speculative watch item rather than a high-conviction buy signal. Investors should monitor Viridian for launch execution and payer coverage decisions before assigning material value.

1 total filings
· daily

New Drug Approvals (Original) — July 02, 2026

During this single-day period, the FDA approved 1 new drug application categorized as 'Other' (FALLBACK type), with 0 NMEs, 0 biosimilars, and 0 label expansions. The sole approval was VELIGROTUG-VVZE (LUMVOA) from VIRIDIAN THERAPEUTICS INC, which received a bullish signal (strength 8/10, materiality 8/10) despite being designated as an NME. No dominant therapeutic area theme emerged due to the single approval, but the high-conviction signal centers on VIRIDIAN's execution capability in bringing a novel therapy to market. Key risks include the lack of disclosed commercial data (peak sales, exclusivity, pricing power, market position), which limits near-term valuation assessment. Investors should monitor VIRIDIAN's launch strategy and payer coverage decisions as critical catalysts.

1 total filings
· daily

DOD Defense Contracts Intelligence — July 02, 2026

The single contract analyzed for July 2, 2026, is a $108.7 million Department of Defense award to PACIFIC TECH CONSTRUCTION INC, representing the entirety of the period's obligation. This is a high-conviction bullish signal (materiality 8/10) but carries significant information gaps—annual revenue, pricing risk, and competition dynamics are all unknown. The award is defense-related, aligning with DOD infrastructure or construction priorities, but the lack of competitive moat or sector context limits actionable conclusions. Key risk: the contract's November 2023 award date suggests it may be subject to continuing resolution (CR) uncertainty if options or modifications are pending in the current fiscal environment.

1 total filings
· daily

New Federal Contractors — July 02, 2026

This digest covers five contracts totaling $1.80 billion, all civilian-awarded with zero defense-related obligations, underscoring a pronounced shift toward non-DOD spending in this sampling. The dominant theme is stable but non-cyclical civilian IT and housing support, led by Carrington Mortgage Services' $970M HUD/Ginnie Mae subservicing award—the highest-conviction signal in the stream. Accenture Federal Services' $402M DOE IT BPA faces a near-term revenue cliff if options are not exercised, while the IRS's fully delivered $139M Microsoft licensing deal is historical. The only contract flagged as bullish is Pacific Tech Construction's $109M DoD award, but data gaps limit confidence. Key risks include Carrington's sole-source pricing pressure and Accenture's impending option expiration.

5 total filings
· daily

Significant Contract Modifications ($10M+) — July 02, 2026

This digest covers $1.80 billion in government contract obligations from July 2, 2026, with zero defense-related awards—a stark civilian-only profile. The dominant theme is HUD housing finance, driven by a single $970M non-compete award to Carrington Mortgage Services for Ginnie Mae subservicing, which accounts for over half the total value. The highest-conviction signal is the $108.7M defense contract to Pacific Tech Construction, the only bullish signal in the set, though its sparse data limits actionable insight. Key risks include Carrington's sole-source pricing risk and Accenture Federal Services' near-term revenue cliff as its DOE IT contract approaches expiration. Investors should monitor HUD's recompete strategy for Ginnie Mae services and the exercise of Accenture's options before April 2024.

5 total filings
· daily

Contract Deobligations Alert — July 02, 2026

This digest covers $1.80 billion in total obligations across five contracts, all civilian (0% defense), with a dominant theme of large-scale, non-competitive service awards to HUD and DOE. The highest-conviction signal is the $970M sole-source Ginnie Mae subservicing award to Carrington Mortgage Services LLC, which provides stable, multi-year revenue but carries execution risk due to time-and-materials pricing. A key risk is the $401.7M Accenture Federal Services DOE IT contract nearing its April 2024 option exercise deadline, creating a near-term revenue cliff. The lone bullish signal is a $108.7M DoD construction award to Pacific Tech Construction Inc, though limited data reduces conviction. Overall, the digest points to civilian agency reliance on sole-source and time-and-materials contracts, which offer revenue stability but limited margin expansion for contractors.

5 total filings
· daily

Contract Option Exercises — July 02, 2026

This digest covers $1.8 billion in contract option exercises from July 2, 2026, with a striking 0/5 defense-related split, making this a purely civilian-sector story. The dominant theme is housing and financial services, led by a massive $970M non-compete award to Carrington Mortgage Services LLC from HUD for Ginnie Mae subservicing, which accounts for over half of the total obligation. The highest-conviction signal is a bullish $108.7M defense contract to Pacific Tech Construction Inc, though its sparse data limits actionable depth. A key risk is the $401.7M Accenture Federal Services contract at DOE, which faces a near-term revenue cliff if options are not exercised by April 2024. The digest is dominated by neutral signals (4/5), reflecting stable but unexciting civilian agency spending with no clear growth catalyst.

5 total filings
· daily

Federal IT & Cybersecurity Contracts — July 02, 2026

This digest covers $541.1M in civilian federal IT contracts awarded to Accenture Federal Services LLC and Dell Federal Systems L.P., with zero defense-related awards. The dominant theme is civilian agency IT modernization, led by a $401.7M Department of Energy (DOE) time-and-materials BPA call to Accenture Federal Services, which represents 74% of total obligated value and carries medium pricing risk. The highest-conviction signal is neutral: Accenture's contract is nearing its current performance end (April 2024), creating a near-term revenue cliff unless options are exercised. A key risk is the time-and-materials pricing structure, which limits margin expansion for Accenture, while Dell's $139.4M IRS Microsoft subscription order is fully performed and offers no forward catalyst. No bullish or bearish signals were identified; both contracts are rated neutral with average signal strength of 5.0/10.

2 total filings
· daily

All DOE Contracts — July 02, 2026

This digest covers a single, large civilian contract from the Department of Energy (DOE) to Accenture Federal Services LLC, valued at $401.7M obligated (up to $660M with options). The contract is entirely non-defense, reflecting a significant DOE IT modernization push. The highest-conviction signal is neutral: the contract provides a substantial revenue stream but carries medium risk due to time-and-materials pricing and a near-term revenue cliff as the current performance period ends in April 2024. Key risk includes potential non-exercise of options, which would create a sudden revenue gap for Accenture Federal Services.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 02, 2026

The July 2, 2026 mega-contracts stream reveals a $1.8B aggregate with a stark 0/5 defense split, signaling a civilian-heavy procurement environment dominated by a single $970M HUD award to Carrington Mortgage Services. The highest-conviction signal is a bullish $108.7M defense contract to Pacific Tech Construction Inc, though its sparse data limits actionable depth. The dominant theme is stable, service-oriented civilian spending (HUD, DOE, NASA, IRS) rather than high-growth defense tech. A key risk is the near-term revenue cliff for Accenture Federal Services at the DOE, whose $401.7M contract expires in April 2024, creating uncertainty for its parent Novetta Solutions.

5 total filings
· daily

All DOD Contracts — July 02, 2026

In this single-contract period, the Department of Defense awarded a sole $108.7 million obligation to PACIFIC TECH CONSTRUCTION INC, representing 100% defense spending with no civilian agency activity. The contract carries a bullish signal with high materiality (8/10), but the lack of pricing, competition, or sector details introduces significant uncertainty. The dominant theme is a large, opaque infrastructure or construction award, likely tied to Pacific theater priorities. Key risk: the absence of competitive moat or revenue context makes it difficult to assess durability or margin impact for the contractor.

1 total filings